No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
CNTG Centogene
- 0.3800
- -0.0103-2.64%
Close Jun 28 16:00 ET
- 0.3896
- +0.0096+2.53%
Post 17:39 ET
11.02MMarket Cap-279P/E (TTM)
0.3999High0.3800Low15.59KVolume0.3856Open0.3903Pre Close5.99KTurnover0.13%Turnover RatioLossP/E (Static)29.00MShares1.680052wk High-0.41P/B4.48MFloat Cap0.340052wk Low--Dividend TTM11.78MShs Float28.7109Historical High--Div YieldTTM5.10%Amplitude0.3400Historical Low0.3840Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Centogene Jumps on Hookup With Critical Path
Express News | Centogene Shares Are Trading Higher After the Company Signed a Memorandum of Understanding With C-Path for Collaboration in Lysosomal Disease Research and Drug Development
Express News | Centogene And C-Path Sign MOU For Collaboration In Lysosomal Disease Research And Drug Development
C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development
TUCSON, Ariz. and CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- Critical Path Institute (C-Path), a leader in forming collaborations that accelerate drug development, and Centogene
CENTOGENE Shareholders Approve Key Resolutions
Press Release: CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting
CENTOGENE N.V. (Nasdaq: CNTG) (the "Company"), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company's 2024 Annual General Meeting. Shareholders voted in favor of all proposals.
Comments
$Centogene(CNTG.US$ Benzinga· 2 mins ago
Centogene And C-Path Sign MOU For Collaboration In Lysosomal Disease Research And Drug Development
Centogene And C-Path Sign MOU For Collaboration In Lysosomal Disease Research And Drug Development
$Centogene(CNTG.US$
NEWS (LATE)
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
Centogene (Nasdaq: CNTG) has secured approximately $20 million in funding through an expanded relationship with Lifera, a biopharma company owned by Saudi Arabia's Public Investment Fund (PIF). This includes a $15 million purchase of Centogene’s accounts receivables and additional investments in their joint venture. The financing bolsters Centogene’s liquidity, supporting operations and strategic i...
NEWS (LATE)
CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position
Centogene (Nasdaq: CNTG) has secured approximately $20 million in funding through an expanded relationship with Lifera, a biopharma company owned by Saudi Arabia's Public Investment Fund (PIF). This includes a $15 million purchase of Centogene’s accounts receivables and additional investments in their joint venture. The financing bolsters Centogene’s liquidity, supporting operations and strategic i...
2
$Centogene(CNTG.US$CENTOGENE Entered Into Agrements With Lifera; Provides ~$20M Funding
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg